Articles |
From the Pharma Division, Preclinical Research, F. HoffmannLa Roche Ltd, Basel, Switzerland.
Correspondence to Daniel Kirchhofer, PhD, Pharma Division, Preclinical Research, F. HoffmannLa Roche Ltd, Grenzacherstr 124, CH-4002 Basel, Switzerland.
Abstract The role of tissue factor/factor VIIa (FVIIa) and
factor VIIIa/factor IXa (FVIIIa/FIXa) complexes in thrombus formation
was examined in a human ex vivo blood flow system by use of active
siteblocked FVIIa (FVIIai) and FIXa (FIXai) as selective
inhibitors. Blood was drawn directly from the veins of
volunteers into a mixing device where FVIIai and FIXai were mixed with
flowing blood. The blood then entered parallel-plate chambers
containing coverslips coated with human fibrillar collagen or tissue
factorexpressing cell layers of tumor necrosis
factor
stimulated human endothelial cells, human
smooth muscle cells, and J82 cells. Exposure of stimulated
endothelial cells to blood flowing at a venous shear
rate of 65/s led to fibrin deposition, which was inhibited by infusion
of FVIIai (IC50, 3 nmol/L), as quantified by
microdensitometry of fibrin-stained coverslips. Whereas FIXai (600
nmol/L) was only a weak inhibitor, FVIIai (60 nmol/L)
reduced fibrinopeptide A (FPA) plasma levels from
504±79 to 171±27 ng/mL and concomitantly inhibited platelet
thrombus deposition. Similarly, experiments with smooth muscle
cells and J82 cells showed that FVIIai but not FIXai efficiently
reduced FPA levels. Conversely, with tissue factorfree collagen,
which induces platelet-dependent fibrin formation, infusion of
FIXai but not of FVIIai inhibited fibrin deposition
(IC50, 8 nmol/L) and reduced FPA levels from 55±8
to 9±5 ng/mL. However, FIXai did not affect the number of platelet
thrombi deposited on collagen. The results suggest that fibrin
formation on tissue factorexpressing cellular surfaces is initiated
by tissue factor/FVIIadependent direct activation of factor X, while
on the tissue factorfree collagen surface, factor X activation and
subsequent fibrin formation is dependent on the platelet
FVIIIa/FIXa complex.
Key Words: tissue factor blood platelets factor VII factor IX thrombosis
This article has been cited by other articles:
![]() |
E. I. Lev, J. D. Marmur, M. Zdravkovic, J. I. Osende, J. Robbins, J. A. Delfin, M. Richard, E. Erhardtsen, M. S. Thomsen, A. M. Lincoff, et al. Antithrombotic Effect of Tissue Factor Inhibition by Inactivated Factor VIIa: An Ex Vivo Human Study Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1036 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Rauch, J. I. Osende, V. Fuster, J. J. Badimon, Z. Fayad, and J. H. Chesebro Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences Ann Intern Med, February 6, 2001; 134(3): 224 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Orvim, R. M. Barstad, L. Orning, L. B. Petersen, M. Ezban, U. Hedner, and K. S. Sakariassen Antithrombotic Efficacy of Inactivated Active Site Recombinant Factor VIIa Is Shear Dependent in Human Blood Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3049 - 3056. [Abstract] [Full Text] |
||||
![]() |
B. B. Sorensen, E. Persson, P.-O. Freskgard, M. Kjalke, M. Ezban, T. Williams, and L. V. M. Rao Incorporation of an Active Site Inhibitor in Factor VIIa Alters the Affinity for Tissue Factor J. Biol. Chem., May 2, 1997; 272(18): 11863 - 11868. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kirchhofer, M. A. Riederer, and H. R. Baumgartner Specific Accumulation of Circulating Monocytes and Polymorphonuclear Leukocytes on Platelet Thrombi in a Vascular Injury Model Blood, February 15, 1997; 89(4): 1270 - 1278. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |